Oppenheimer & Co. Inc. Buys 61,829 Shares of Pfizer Inc. $PFE

Oppenheimer & Co. Inc. raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.6% during the third quarter, according to its most recent filing with the SEC. The firm owned 703,405 shares of the biopharmaceutical company’s stock after purchasing an additional 61,829 shares during the period. Oppenheimer & Co. Inc.’s holdings in Pfizer were worth $17,923,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Norges Bank acquired a new position in shares of Pfizer during the second quarter valued at about $2,270,157,000. Vanguard Group Inc. grew its position in Pfizer by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after purchasing an additional 10,198,330 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Pfizer by 43.4% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock valued at $453,747,000 after purchasing an additional 5,662,309 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Pfizer by 75.0% in the third quarter. Assenagon Asset Management S.A. now owns 8,689,103 shares of the biopharmaceutical company’s stock worth $221,398,000 after buying an additional 3,722,531 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of Pfizer by 84.9% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,561,946 shares of the biopharmaceutical company’s stock worth $183,302,000 after buying an additional 3,472,240 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 2.8%

Shares of NYSE:PFE opened at $27.24 on Monday. The company has a market capitalization of $154.88 billion, a price-to-earnings ratio of 20.03 and a beta of 0.47. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.69. The business has a 50-day moving average price of $25.61 and a 200 day moving average price of $25.10. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The business had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same period last year, the firm earned $0.63 earnings per share. The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. Sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.3%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is currently 126.47%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on PFE. The Goldman Sachs Group reissued a “neutral” rating and set a $26.00 price target on shares of Pfizer in a research report on Wednesday, November 5th. Scotiabank assumed coverage on shares of Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price for the company. Citigroup initiated coverage on shares of Pfizer in a report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target on the stock. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research note on Wednesday, February 4th. Finally, Zacks Research downgraded Pfizer from a “hold” rating to a “strong sell” rating in a research note on Monday, January 26th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus price target of $28.06.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 earnings beat and GLP‑1 topline: Pfizer reported upside on revenue and EPS and released positive Phase 2b results for its lead GLP‑1 candidate (strong placebo‑adjusted weight loss), which helped lift sentiment around a new growth leg. Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
• Positive Sentiment: Management outlines obesity strategy: Pfizer execs signaled the company is “back in the obesity race,” emphasizing development plans and commercialization intent after the encouraging GLP‑1 data. Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data
• Positive Sentiment: FDA grants Priority Review for HYMPAVZI sBLA: The agency accepted a supplemental biologics license application to expand HYMPAVZI’s indication to pediatric and inhibitor populations in hemophilia, which could broaden revenue opportunity if approved. FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA
• Positive Sentiment: Mid‑stage obesity candidate complete: Pfizer announced completion of a mid‑stage trial for PF‑07976016, adding to its GLP‑1/obesity development cadence and potential registration pathway. Pfizer Completes Mid-Stage Trial of New Obesity Drug Candidate PF-07976016
• Positive Sentiment: Pipeline & M&A push into oncology and obesity: Analysts and coverage note Pfizer is lining up ~20 pivotal studies after ~ $9B of 2025 M&A, leaning on Seagen assets and AI tools to accelerate R&D — a multi‑year growth story. Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push
• Positive Sentiment: Income investor attention: Pfizer appears on recent high‑yield dividend stock lists, which can support demand from yield‑focused investors. 3 High-Yield Dividend Stocks Perfect For Retirees
• Neutral Sentiment: Cost‑savings / affordability program: Pfizer launched a TrumpRx program offering discounts on ~30 medicines — positive for patient access and PR, but the near‑term financial impact is unclear. Pfizer Launches Cost-Savings Program on TrumpRx
• Neutral Sentiment: Analyst views mixed: Coverage notes cautious upside — bullish pipeline/AI drivers balanced by execution risk, time to commercialization, and competitive pressure in GLP‑1s. Pfizer Stock Forecast: Trending Analysts See Cautious Upside
• Negative Sentiment: Early‑stage trial halted: Pfizer paused an early‑stage study for PF‑07258669 in older adults, introducing a specific clinical risk that could require program adjustments. Pfizer Halts Early-Stage Trial for PF-07258669 in Older Adults

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.